Nivolumab in non-small cell lung cancer: Indication of major added benefit for under 75-year-olds

Younger patients with non-small cell lung cancer in good general condition survive notably longer with the new drug than with the comparator therapy. The added benefit is non-quantifiable in older patients, say reviewers.

from Today's Healthcare News -- ScienceDaily http://ift.tt/1YgSgXr